NCT04067986Unknown1 期
Camrelizumab Combined With Apatinib in the Treatment of Patients With Advanced Gastric Cancer and Colorectal Cancer：One-arm Exploratory Clinical Trial
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 入组人数
- 62
- 试验地点
- 1
- 主要终点
- Objective response rate
研究概览
简要总结
The efficacy and safety of the use of Camrelizumab combined with Apatinib
详细描述
To evaluate the clinical efficacy and safety of Camrelizumab combined with Apatinib in the treatment of patients with advanced gastric cancer and colorectal cancer.
The 62 patients were enrolled in a 2-week regimen with 200mg Camrelizumab given intravenously every two weeks and 250mg apatinib mesylate every 4 weeks for a treatment cycle until progressive or intolerable，then the objective remission rate(ORR) was calculated.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18 - 75 years；
- •Patients with histologically or cytologically confirmed advanced or metastatic gastric cancer and colorectal cancer.
- •Patients who had previously progressed after receiving standard second-line advanced treatment；
- •Patients with at least one evaluable or measurable lesions as per RECIST version 1.1 （CT scan length and diameter of tumor lesion≥10mm，CT scan of lymph node lesion was short diameter≥15mm，scan slice thickness 5mm；）
- •ECOG performance status (PS) 0 - 2；
- •Life expectancy of at least 3 months；
- •Patients with adequate organ function at the time of enrollment as defined below:
- •Blood routine examination standard：（without blood transfusion within 14 days before enrollment）
- •WBC≥3.0×109/L
- •ANC ≥ 1.5×109/L，
- •PLT ≥ 80×109/L；
- •Biochemical examination shall meet the following standards：
- •BIL <1.5 times the upper limit of normal（ULN），
- •ALT and aspartate aminotransferase (AST) <2.5×upper limit of normal (ULN)，If liver metastasis is present，ALT and AST<5ULN ；
- •Serum creatinine Cr≤1ULN，Serum creatinine >50ml/min（Cockcroft-Gault math）
- •Women of childbearing age in the serum or urine pregnancy test is negative within 7 days prior to study enrollment and must be Non-lactating patients，and agree to use contraceptives (such as intrauterine devices, contraceptives or condoms) during the study period and within 8 months after the end of the study； males should agree to patients who must use contraception during the study period and within 8 months after the end of the study period
- •Subjects voluntarily joined the study, signed informed consent, good compliance, and followed up;
排除标准
- •Except for other malignant tumors, basal cell carcinoma of the skin and cervical cancer in situ in the past 5 years；
- •Patients who have undergone systemic chemotherapy, radiotherapy, surgery, hormone therapy, or immunotherapy <2 weeks before enrollment；
- •With severe heart, liver, lung and kidney disease；Significant neurological or psychiatric disorders；Patients with partial or complete gastrointestinal obstruction；
- •Patients with a large amount of pleural effusion or ascites requiring drainage；
- •Patients with symptomatic brain metastasis；
- •Patients with hypertension that is difficult to control (systolic blood pressure ≥140 mmHg and diastolic blood pressure ≥90 mmHg) despite treatment with several hypotensive agents; Patients with acute coronary syndrome (including myocardial infarction and unstable angina), and with a history of coronary angioplasty or stent placement performed within 6 months before enrollment；Patients with acute coronary syndrome（included QTc male>450ms，female>470ms）and cardiac dysfunction；
- •Women who are pregnant or breastfeeding；
- •Patients with concurrent autoimmune disease, or a history of chronic or recurrent autoimmune disease;
- •Patients with concurrent autoimmune disease, or a history of chronic or recurrent autoimmune disease: included HIV positive or a history of organ transplantation and allogeneic bone marrow transplantation;
- •Patients with interstitial lung disease with symptoms or signs of activity；
- •Patients with a risk of gastrointestinal bleeding may not be enrolled, including the following: (1) active digestive ulcer lesions and fecal occult blood (++); (2) nausea and hematemesis within 2 months Medical history. Simple fecal occult blood (+) is not an exclusion criterion；Coagulation abnormalities （INR>1.5、APTT>1.5ULN）；
- •Urine protein ≥ ++ or confirmed 24 hour urine protein quantitation；
- •Patients with non-healing wound, non-healing ulcer, or non-healing bone fracture;
- •Patients with a seizure disorder who require pharmacotherapy；
- •Patients with a history of hypersensitivity to any of the study drugs, similar drugs, or excipients；
- •The investigator believes that there are any conditions that may damage the subject or result in the subject being unable to meet or perform the research request;
- •participated in other clinical studies before and during treatment；
研究组 & 干预措施
Camrelizumab + Apatinib
Other
Camrelizumab + Apatinib
干预措施: Camrelizumab (Drug)
Camrelizumab + Apatinib
Other
Camrelizumab + Apatinib
干预措施: Apatinib (Drug)
结局指标
主要结局
Objective response rate
时间窗: one year
Objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumours (RECIST) version. 1.1, and immune-related (ir) RECIST
次要结局
- Incidence of Treatment-Emergent Adverse-Events(one year)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal CarcinomaNasopharyngeal CarcinomaNCT04548271Sun Yat-sen University25
Unknown
1 期
Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCLDiffuse Large B Cell LymphomaHigh-grade B-cell LymphomaFollicular Lymphoma Grade IIIbTransformed LymphomaEBV-Positive DLBCL, NosALK-Positive Anaplastic Large Cell LymphomaNCT04476459Huiqiang Huang33
已完成
1 期
A Phase Ib/II Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract CancerLocally Advanced Biliary Tract CancerMetastatic Biliary Tract CancerNCT05742750Sun Yat-sen University49
Unknown
2 期
Camrelizumab in Combination With Apatinib Plus NK Cell for Advanced HCCHepatocellular CarcinomaNCT05171309Nanfang Hospital, Southern Medical University35
招募中
不适用
A Real-world Study of Camrelizumab Combined With Apatinib Mesylate in Unresectable Hepatocellular CarcinomaHepatocellular CarcinomaNCT05409482Meng Chao Hepatobiliary Hospital of Fujian Medical University300